Feature|Videos|January 2, 2025
Final Thoughts
The future of CAR T-cell therapies will continue to improve as they expand to other patients in need.
Advertisement
Episodes in this series
The panelists provide their closing thoughts on CAR T-cell therapies and what they look forward to as these therapies become popular beyond cancer, extending to autoimmune diseases as well. There is hope to remove manufacturing bottleneck so patient demand and access can improve.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Makes Leadership Overhaul Following Commissioner Makary’s Departure: Report
2
Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates
3
FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry
4
The Risks and Benefits of FDA Reviewing Real-Time Data
5